Joshua Bauml
Papers
14
Total Citations
452
H-Index
9
About
Joshua Bauml is a leading head and neck oncologist whose research focuses on de-escalation strategies and surgical innovation for human papillomavirus (HPV)-related oropharyngeal cancer. His major contributions center on refining treatment approaches to reduce morbidity while maintaining excellent oncologic outcomes. Bauml’s landmark Phase 2 AVOID trial (167 citations) demonstrated that omitting the primary tumor bed from radiation after transoral robotic surgery (TORS) is safe for select patients, paving the way for less toxic therapy. He has also pioneered TORS-assisted endoscopy for identifying occult primary tumors (69 citations), addressing a critical diagnostic challenge. His work on quality of life shows that proton therapy significantly improves patient well-being compared to conventional radiation (48 citations). Bauml’s research consistently emphasizes personalized, risk-adapted care—examining outcomes in older patients, HPV-negative disease, and those with adverse features. With over 400 cumulative citations, his studies have shaped guidelines for de-intensified treatment, salvage strategies for recurrence, and sex-based differences in outcomes. A sought-after collaborator, Bauml’s work balances rigorous evidence with a patient-centered focus, making him a key figure in modern head and neck oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10